Search clinical trials for: Dalpiciclib

Total 49 results

Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
Fudan University

Recruiting

Abemaciclib, Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Breast Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

Early Breast Cancer

China
RenJi Hospital

Not yet recruiting

Dalpiciclib in HR+/HER2- ABC

Advanced Breast Cancer

China
Fengzhi Feng

Recruiting

Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors

Recurrent Ovarian Carcinoma

China
West China Hospital

Recruiting

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

Esophageal Squamous Cell Carcinoma

China
Risen (Suzhou) Pharma Tech Co., Ltd.

Recruiting

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Advanced Solid Tumors

China
Zhongzheng Xiang

Not yet recruiting

Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
Shandong Suncadia Medicine Co., Ltd.

Recruiting

Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

Unresectable or Metastatic Breast Cancer

China
Tongji Hospital

Recruiting

Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer

Breast Cancer

China
Zhejiang Cancer Hospital

Recruiting

Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed

China
West China Hospital

Recruiting

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas

Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Hebei Medical University Fourth Hospital

Recruiting

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Shuangyue Liu

Not yet recruiting

Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy

Breast Cancer

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma

Sarcoma

China
Fudan University

Recruiting

Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer (BCTOP-L-M01)

Breast Cancer | Advanced Breast Cancer

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)

Advanced Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Breast Cancer

China
Yantai Yuhuangding Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

HER2 Low Advanced or Metastatic Breast Cancer
Fudan University
Chongqing University Cancer Hospital; Sun Yat-sen University; Peking University... and other collaborators

Recruiting

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

Breast Cancer Metastatic

China
Fudan University
Chongqing University Cancer Hospital; Sun Yat-sen University; Peking University... and other collaborators

Recruiting

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Breast Cancer Metastatic

China
Sun Yat-sen University

Recruiting

CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC

Nasopharyngeal Carcinoma

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

China
Second Affiliated Hospital, School of Medicine,...
GeneCast Biotechnology Co., Ltd.

Recruiting

Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)

Luminal B/HER2-negative Breast Cancer

China
Shengjing Hospital

Recruiting

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

Breast Cancer

China
Universitaire Ziekenhuizen KU Leuven

Recruiting

Buspirone for Weak or Absent Esophageal Peristalsis

Dysphagia, Esophageal

Belgium
Fudan University
Chongqing University Cancer Hospital; Sun Yat-sen University; Peking University... and other collaborators

Recruiting

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Breast Neoplasm | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor

China
Beijing 302 Hospital

Not yet recruiting

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

HR+/HER2- Advanced Breast Cancer

China
Fudan University

Recruiting

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N)

Breast Cancer | Breast Neoplasm | Breast Tumors | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer | Triple-Negative Breast Cancer (TNBC)

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Breast Neoplasm Female
Hebei Medical University Fourth Hospital

Not yet recruiting

Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

Breast Cancer
Fudan University

Not yet recruiting

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Metastatic Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of SHR6390 in Renal Insufficiency and Healthy Subjects

Breast Cancer

China
The Affiliated Hospital of Qingdao University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

Breast Cancer
Hebei Medical University Fourth Hospital

Not yet recruiting

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

Solid Tumor
Fujian Cancer Hospital

Not yet recruiting

the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy

Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology | The TNM (8th) Phase is IV | With EGFR Mutations | Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment | Male or Female | The Age of 18 Years Old or... and other conditions
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer (FIND)

Advanced/Metastatic Colorectal Cancer

China
Fujian Medical University Union Hospital

Not yet recruiting

Dalpiciclib Plus Letrozole and Capecitabine

Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Metastatic Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

Advanced Breast Cancer

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Breast Neoplasms

China
Shengjing Hospital

Recruiting

Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC

Breast Cancer

China
First Affiliated Hospital of Zhejiang University

Recruiting

Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Estrogen Receptor Positive Tumor

China
Fudan University

Active, not recruiting

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Breast Cancer

China
Henan Cancer Hospital

Active, not recruiting

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Metastatic Breast Cancer

China
Fudan University
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer (PLEASURABLE)

Breast Cancer

China
Emotional Brain NY Inc.

Completed

Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems

Hypoactive Sexual Desire Disorder

United States

3

Subscribe